Stocks Clock Fourth...
Health Care: Drugs
Advanced Cell Tech Inc. (ACTC: OTC)
$0.07 0.00 | -0.27%
05/17/13 - 03:59 PM ET
Latest Dividend:0.00
Latest Dividend Yield:0.00%
Dividend Ex-Date:12/31/69
Price Earnings Ratio:n/a
Price Earnings Comparisons:
| ACTC | Sector Avg. | S&P 500 |
|---|---|---|
| n/a | 0.00 | 17.70 |
Price Performance History (% change):
| 3 Mo | 1 Yr | 3 Yr |
|---|---|---|
| -0.92 | 3.89 | -6.25 |
| GROWTH | 12 Mo | 3 Yr | CAGR |
|---|---|---|---|
| Revenue | -7.90 | -0.67 | -0.31 |
| Net Income | -0.22 | 0.00 | |
| EPS | -0.86 | 0.00 |
Earnings for ACTC:
| EBITDA | -21.00 |
| REVENUE | 466.49K |
Average Earnings Estimates
| Qtr (12/07) | Qtr (03/08) | FY (12/07) | FY (12/08) | |
|---|---|---|---|---|
| Average Estimate | $n.a. | $n.a. | $n.a. | $n.a. |
| Number of Analysts | 0 | 0 | 0 | 0 |
| High Estimate | $n.a. | $n.a. | $n.a. | $n.a. |
| Low Estimate | $n.a. | $n.a. | $n.a. | $n.a. |
| Prior Year | $n.a. | $n.a. | $n.a. | $n.a. |
| Growth Rate (Year over Year) | n.a.% | n.a.% | n.a.% | n.a.% |
Portfolios with ACTC
- Portfolio NameUser Type
- UserKJ Stocks
- UserMark
- UserBiotech88
- UserThe Jayden Project
- Userwright stocks
- UserRimp's Stockpicks
- UserMy Portfolio
- User2
- User1
- UserRAPTOR LAST 2
Latest ACTC Headlines from TheStreet
- Thursday's Small-Cap Winners & Losers 06.21.07 | 04:06 pm
Press Releases for ACTC
- Advanced Cell Technology, Cytomedix And Mesoblast To Provide Corporate And Clinical Updates At Regen Med Investor Day - PR Newswire 04.09.13 | 12:04 pm
- ACT’s Chief Scientific Officer Dr. Robert Lanza To Deliver The Nerem Lecture 2013 At The 17th Annual Hilton Head Workshop - Business Wire 03.22.13 | 08:03 am
- Advanced Cell Technology Receives Approval From Data Safety Monitoring Board (DSMB) To Initiate Treatment Of Third Patient Cohort In All Three Clinical Trials - Business Wire 03.14.13 | 08:03 am
- ACT’s Dr. Robert Lanza Voted Top 4 “Most Influential People On Stem Cells” - Business Wire 03.12.13 | 08:03 am
- Advanced Cell Technology To Present At BIO-Europe Spring 2013 - Business Wire 03.08.13 | 12:03 pm
- Advanced Cell Technology Announces Fourth-Quarter And Year-end Results - Business Wire 03.07.13 | 04:03 pm
- Advanced Cell Technology To Announce Fourth Quarter And Year-end Results On Thursday March 7th - Business Wire 03.04.13 | 09:03 am
- ACT’s Chief Scientific Officer Robert Lanza, MD, Appointed Editor-in-Chief Of BioResearch Open Access Journal - Business Wire 02.11.13 | 11:02 am
- ACT’s Clinical Partner Receives FDA Approval To Initiate Clinical Trial Using The Company’s HESC-derived Cells To Treat Severe Myopia - Business Wire 02.11.13 | 08:02 am
- Advanced Cell Technology To Present At 15th Annual BIO CEO & Investor Conference - Business Wire 02.08.13 | 08:02 am
Partner Headlines for ACTC
- First patients picked for stem cell vision trials - Reuters 06.16.11 | 09:06 am
- UPDATE 3-US court backs federal embryonic stem cells funds - Reuters 04.29.11 | 02:04 pm
- FDA OKs second Advanced Cell stem cell trial - Reuters 01.03.11 | 11:01 am
- UPDATE 2-Second US company gets stem cell go-ahead - Reuters 11.22.10 | 02:11 pm
- UPDATE 3-First patient treated in Geron stem cell trial - Reuters 10.11.10 | 03:10 pm
- Geron given FDA go-ahead for stem cells trial - Financial Times 07.30.10 | 06:07 pm
